Evidence map›Paper›PMID 33564774›Full record

ArticlemedRxiv : the preprint server for health sciences2021

RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES.

Kathryn C Fitzgerald, Christopher A Mecoli, Morgan Douglas, Samantha Harris, Berna Aravidis, Jemima Albayda, Elias S Sotirchos, Ahmet Hoke, Ana-Maria Orbai, Michelle Petri and 24 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 1 institution in 1 country.

Kathryn C FitzgeraldDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Christopher A MecoliDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Morgan DouglasDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Samantha HarrisDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Berna AravidisDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Jemima AlbaydaDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Elias S SotirchosDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ahmet HokeDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ana-Maria OrbaiDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Michelle PetriDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lisa Christopher-StineDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Alan N BaerDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Julie J PaikDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Brittany L AdlerDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Eleni TiniakouDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Homa TimlinDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Pavan BhargavaDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Scott D NewsomeDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Arun VenkatesanDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Vinay ChaudhryDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Thomas E LloydDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Carlos A PardoDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Barney J SternDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Mark LazarevDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Brindusa TrutaDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Shiv SaidhaDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Edward S ChenDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Michelle SharpDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Nisha GilotraDepartment of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Edward K KasperDepartment of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Allan C GelberDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Clifton O BinghamDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ami A ShahDivision of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ellen M MowryDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · US

Funding

Optimizing the Approach to Identify Cancer-Associated MyositisK23AR075898 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MECOLI, CHRISTOPHER · 2019 to 2023
$773k
Circadian Rhythms and Sleep, Structural Neuroimaging and Depression in People with Multiple SclerosisK01MH121582 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FITZGERALD, KATHRYN C. · 2019 to 2022
$675k
NIAMS NIH HHS K23 AR075898NIMH NIH HHS K01 MH121582
6 · The paper itself

Abstract

Background: People with autoimmune or inflammatory conditions who take immunomodulatory/suppressive medications may have a higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. Objective: Assess whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterize pandemic-associated changes to care. Design: Longitudinal registry study. Participants: 4666 individuals with autoimmune or inflammatory conditions followed by specialists in neurology, rheumatology, cardiology, pulmonology or gastroenterology at Johns Hopkins. Measurements: Periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare. Results: A total of 265 (5.6%) developed COVID-19 over 9 months of follow-up (April-December 2020). Patient characteristics (age, race, comorbidity, medication exposure) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in multivariable models incorporating behavior and other potential confounders (OR: 1.43; 95%CI: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95%CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95%CI: 1.24, 2.28), and chronic kidney disease (OR: 1.76; 95%CI: 1.04, 2.97) were each associated with higher odds of COVID-19. Pandemic-related disruption to care was common. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions. Individuals experiencing changes to employment or income were at highest odds of care disruption. Limitations: Results may not be generalizable to all patients with autoimmune or inflammatory conditions. Information was self-reported. Conclusions: Exposure to glucocorticoids may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions.

Identifiers

PMID33564774
PMCPMC7872366
OpenAlexW3127069434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.